Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Parallel Group, Double-blind, Phase 2 Trial to Evaluate Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease

NCT04189432 is registered in ClinicalTrials.gov with SCM Lifescience Co., LTD. as lead sponsor.

NCT NCT04189432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04189432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Parallel Group, Double-blind, Phase 2 Trial to Evaluate Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease
Lead sponsor
SCM Lifescience Co., LTD.
Phase
Phase 2
Overall status
Unknown status
Start date
September 28, 2016
Completion date
September 30, 2024
Enrollment
84 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host-disease